



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Aflibercept (Eylea®)
Indication under review	Visual impairment due to myopic choroidal neovascularisation
Policy No:	APC 135
Date of Issue:	November 2016
Review Date:	November 2019
Policy Statement: Aflibercept is recommended as an option for the treatment of visual impairment due to myopic choroidal neovascularisation (CNV). Sequential use after ranibizumab (Lucentis®) is not recommended.	
Traffic Light Status	Red
Key Points considered: <ul style="list-style-type: none">• Intravitreal aflibercept is a vascular endothelial growth factor (VEGF) inhibitor that is already licensed for several ophthalmic conditions and is NICE approved for wet age related macular degeneration, diabetic macular oedema and retinal vein occlusions.• The committee noted the evidence presented in NICE Evidence Summary New Medicine 76.• The committee also noted that there have not been clinical trials in patients who have previously undergone treatment for CNV. This treatment therefore cannot be used in patients previously treated with ranibizumab.	
References: Nice.org.uk/guidance/esnm76	
Date taken to APC:	2 nd November 2016
Date Ratified by GPMOC on Behalf of the Board:	16 th November 2016